Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ephedra lawsuit

This article was originally published in The Tan Sheet

Executive Summary

NVE Pharmaceuticals may not supplement FDA's administrative record as it proceeds with legal allegations against the agency's ephedra ban, a Third Circuit Court of Appeals judge rules Feb. 7. Thus, NVE may not provide expert affidavits or testimony and may not conduct discovery. The ruling affirms that of an August 2004 ruling by a district judge in Newark, N.J. federal court where the case was originally filed. The case is remanded to the district court for further proceedings in accordance with the opinion of the appellate court. NVE filed the complaint against FDA in March 2004 alleging that the agency could not ban supplements containing ephedrine alkaloids because it did not meet the burden of proof required by DSHEA (1"The Tan Sheet" March 15, 2004, p. 8). The agency also is appealing a Utah federal court ruling in a separate suit against its ephedra ban that was filed by Nutraceutical Corp (2"The Tan Sheet" Nov. 14, 2005, p. 4)...

You may also be interested in...



“No Evidence” Exists That Ephedra Ban Shifted Burden Of Proof, Agency Says

No evidence has been presented that FDA's use of a risk/benefit analysis in its decision to ban ephedra shifted the burden of proof onto industry, the agency says

NVE Takes First Shot At Ephedra Ban: FDA Violated DSHEA, Firm Says

NVE Pharmaceuticals is challenging FDA's ban of ephedra on the grounds the agency did not meet its burden of proving the ingredient unsafe under the Dietary Supplement Health & Education Act

QUOTED. 26 February 2020. Mark Leahey.

In an exclusive interview with Medtech Insight, Mark Leahey, president of the Medical Device Manufacturers Association (MDMA), said the previous four Medical Device User Fee negotiations with the US FDA have set a strong foundation for the industry and the next round of negotiations should focus on tweaking past deals that are already in place. See what MDMA's president, Mark Leahey, said about it here.

Topics

UsernamePublicRestriction

Register

PS099089

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel